NBSE News and Press, NeuBase Therapeutics Inc. From 06/28/23

PITTSBURGH, June 28, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced th...

2023-06-16 10:08:10 ET Gainers: Oncorus ( ONCR ) +264% . Microbot Medical ( MBOT ) +24% . NeuBase Therapeutics ( NBSE ) +19% . Community Health Systems ( CYH ) +8% . Homology Medicines ( FIXX ) +4% . Losers: Panbela Therap...

2023-06-14 09:03:15 ET NeuBase Therapeutics said Wednesday that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20 to regain compliance with Nasdaq's listing rule. The stock split will be effective as of 5:00 p.m. ET on June 14,...

PITTSBURGH, June 14, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today anno...

PITTSBURGH, May 24, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today annou...

Data show that Stealth Editors™ achieve ex vivo gene editing using simple synthetic reagents to harness the cell's own high-fidelity editing machinery Data show that Stealth Editors™ do not elicit a cell-based immunity and promise a non-immunogenic in vivo solution ...

PITTSBURGH, May 16, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced...

2023-05-11 17:22:14 ET NeuBase Therapeutics press release ( NASDAQ: NBSE ): Q1 GAAP EPS of -$0.12 misses by $0.02 . For the quarter ended March 31, 2023, total operating expenses were approximately $4.2 million, consisting of approximately $2.9 million in general and a...

Announced oral presentations at the American Society of Gene & Cell Therapy (“ASGCT”) 26th Annual Meeting to take place on May 16-20, 2023 Company to present additional data showcasing gene editing capabilities at scientific conferences throughout remainder of 2023 ...

PITTSBURGH, May 02, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced two abstracts have been accepte...